Vivek Subbiah: ASCO 24 time to learn the latest and greatest in Tissue Agnostic Precision Medicine
Vivek Subbiah shared on X:
“It’s ASCO 24 time Mark your calendars to learn the latest & greatest in Tissue Agnostic Precision Medicine.
Delighted to join amazing colleagues for a terrific session – ‘Beyond Tumor Types: Advancing Tumor-Agnostic Drug Development & the Role of the Tumor Microenvironment’
- When: 2024 ASCO Annual Meeting
- Who: Drs. Aparna Raj Parikh, MassGeneral News, Mass General Brigham, Harvard Medical School, Marc Ladanyi, Memorial Sloan Kettering Cancer Center, Andy McKenzie, Vivek Subbiah.
- Location: Hall D2
- Time: June 3, 2024 3:00 PM – 4:00 PM CDT
- Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology | Immunotherapy | Developmental Therapeutics—Immunotherapy
The voices of ASCO 24: Omar Abdihamid, Jacob J. Adashek, Two Onc Docs, Darcy Burbage, Fumiko Ladd Chino, Janice Cowden, Devika Das, Aakash Desai, Khalid El Bairi, Jill Feldman, Oncology Brothers, The Fellow On Call, Herbert Loong, Ana I. Velázquez Mañana, Charbel Matar, Shearwood McClelland, Martina Murphy, Rafeh Naqash, Allison Rosen, Ramy Sedhom, Ashley Love Sumrall, Kekoa Taparra, Eleonora Teplinsky, Yüksel Ürün, Shannon Westin.”
Source: Vivek Subbiah/X
.
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA).
He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.
Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world.